Published in final edited form as:

Neuroscience. 2012 January 10; 201: 349–356. doi:10.1016/j.neuroscience.2011.11.004.

Utilization of Adipose-Derived Stem Cells to Fabricate Scaffold-less Tissue Engineered Neural Conduits *In Vitro*

Aaron M. Adams¹, Ellen M Arruda^{2,3,4}, and Lisa M Larkin^{1,3}

¹Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109

²Department of Mechanical Engineering, University of Michigan, Ann Arbor, MI 48109

³Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109

⁴Program in Macromolecular Science and Engineering, University of Michigan, Ann Arbor, MI 48109

Abstract

Peripheral nerve injuries resulting from trauma or disease often necessitate surgical intervention. While the gold standard for such repairs utilizes nerve autografts, alternatives that do not require invasive harvesting of autologous nerve tissues are currently being designed and evaluated. We previously established the use of scaffold-less engineered neural conduits fabricated from primary cells as one such alternative in sciatic nerve repair in rats (Baltich, 2010; Adams 2011). The present study establishes protocols for fabricating neural conduits from adipose-derived stem cells (ASCs) differentiated to either a fibroblast or neural lineage and co-cultured into a three-dimensional scaffold-less tissue engineered neural conduit. Addition of ascorbic acid-2-phosphate and fibroblast growth factor FGF-2 to the medium induced and differentiated ASCs to a fibroblast lineage in over 90% of the cell population, as confirmed by collagen I expression. ASC-differentiated fibroblasts formed monolayers, delaminated and formed 3-D conduits. Neurospheres were formed by culturing ASCs on non-adherent surfaces in serum-free neurobasal medium with the addition of epidermal growth factor EGF and FGF-2. The addition of 10 ng EGF and 10 ng FGF-2 produced larger and more numerous neurospheres than treatments of lower EGF and FGF-2 concentrations. Subsequent differentiation to glial-like cells was confirmed by the expression of S100. ASC-derived fibroblast monolayers and neurospheres were co-cultured to fabricate a three-dimensional scaffold-less tissue engineered neural conduit. Their nerve-like structure and incorporation of glial-like cells which would associate with regenerating axons may make these novel, stem cell derived neural conduits an efficacious technology for repairing critical gaps following peripheral nerve injury.

Keywords

Adipose-derived stem cells (ASC); peripheral nerve repair; nerve conduit; tissue engineering

© 2011 IBRO. Published by Elsevier Ltd. All rights reserved.

Contact: Lisa Larkin PhD, Associate Professor, Molecular and Integrative Physiology, Biomedical Engineering, University of Michigan, Biomedical Science Research Building (BSRB), 109 Zina Pitcher Place, Room #2025, 48109-2200, Phone: (734) 936-8181, Fax: (734) 615-3292, llarkin@umich.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Introduction

Peripheral nerve trauma affects 1 in 1000 people resulting in tissue morbidity and decreased quality of life (Shokouhi, 2005). These traumas can lead to gaps of damaged nerve tissue between viable nerve sections which result in a loss of function. While less significant injuries can be repaired without surgical intervention, injuries which lead to critical nerve gaps require grafts to direct neural regeneration. Autologous nerve grafts from either hosts (autograft) or non-hosts (allograft) are capable of bridging large nerve gaps (Ray, 2009). Autologous nerve grafts are considered the “gold standard” for repairing transected nerves in the peripheral nervous system (Lundborg, 1988; Meek, 2008; Schmidt, 2003). However, autologous nerve grafts possess several limitations. The process of harvesting an autograft involves a separate surgical procedure and can lead to loss of function, donor site neuroma, pain and scarring (Taras, 2005). Additionally, there is a finite amount of nerve tissue available for grafting (Millesi, 1991). On the other hand, allografts may lead to complications associated with host rejection (Ray, 2009). Due to these limitations, considerable research has been devoted to design alternative technologies to bridge critical nerve gaps. Biological and synthetic conduits have been engineered to possess the attributes of autologous nerve grafts without the limitations of availability, donor site morbidity, and the need for two surgical procedures (Taras, 2005).

In order to overcome the limitations of both grafts and current scaffold-based conduit alternatives, our laboratory has previously fabricated three-dimensional (3-D) scaffold-less engineered neural conduits (ENC) utilizing primary fibroblasts and embryonic-derived neural cells (Baltich, 2010). The ENC is similar in structure to native nerve, consisting of a connective tissue exterior sheath and an inner nerve network. The efficacy of the scaffold-less 3-D engineered nerve conduits in allowing axonal regeneration across a 10 mm nerve gap in the tibial nerve of adult Fisher F344 rats has been evaluated (Adams, 2011). While the ENC allowed for axonal regeneration through the 10 mm gap, it was not as efficacious as an autograft in repairing the injured site but nevertheless succeeded in demonstrating a proof of concept of scaffold-less neural cell approaches to nerve repair. Fetal cells are not a relevant cell source for translating these technologies to the clinic; therefore our laboratory shifted focus to the fabrication of ENCs from differentiated adipose-derived stem cells (ASCs). Both embryonic-derived neural cells and ASCs eliminate the need for autograft harvesting. ASCs additionally offer a clinically relevant option.

Mesenchymal stem cells (MSCs) are adult marrow and non-marrow derived stem cells noted for their capability to differentiate into multiple tissue lineages. While bone marrow was the original and most common site for isolating MSCs, stem cell investigations have undergone a paradigm shift with current research focusing on the isolation, characterization, and utilization of adipose-derived stem cells (ASCs) as a cell source for tissue engineering (Mosna 2010, Zhu 2008). Characterization of MSC cell surface markers varies based on the tissue harvested (adipose-derived vs. bone marrow-derived) as well variability has been shown between research groups (Mosna 2010). However, bone marrow-derived stem cells have typically been consistent in positive expression of CD90, CD105, and CD73. The level of expression of these markers in ASCs has not been consistent or reliable for identification. Recently it has been suggested that surface marker CD271 (p75NTR) is not only located on both adipose- and bone marrow-derived stem cells but could also be used as a sole identifying marker for these cells from the heterogeneous population of cells isolated from bone marrow or adipose fat pads (Griesche 2010, Flores 2010).

In both animal and human trials, ASCs have been shown to have promising repair potential. ASCs are currently being investigated in trials involving tissue healing after radiotherapy and treatment of recurrent Crohn's fistulae (Locke 2009). Undifferentiated ASCs have been

shown to increase nerve regeneration in conduit based peripheral nerve repair studies (Santiago 2009). Additionally, differentiated ASCs are being evaluated as fat grafts in reconstruction therapies, as bone grafts in osseous defects, as chondrogenic grafts in joint disease and cartilage regeneration treatments, and as neuronal support in regeneration of axons in the peripheral nervous system resulting from peripheral nerve injuries and deficits in the central nervous system caused by cerebral ischemia (Locke 2011). In some cases the incorporation of ASC-derived neural cells into conduits restored nerve function better than conduits incorporated with Schwann cells (di Summa 2011).

The purpose of this study was to permanently induce adipose-derived stem cells (ASCs) to fibroblast and neural lineages and to co-culture these cells to fabricate and characterize an engineered neural conduit derived solely from ASCs. This study combines the approach of utilizing stem cells in nerve repair technologies with a recently developed technique from our laboratory for fabricating scaffold-less neural conduits (Radtke, 2009; Baltich, 2010). In this study we demonstrate the differentiation of ASCs to fibroblastic and neural lineages, establishment of a co-culture of both cell types, and co-culture fabrication into a 3-dimensional scaffold-less engineered neural conduit.

Methods

Animals and animal care

Female Fischer 344 retired breeder rats (Charles River Laboratories, Wilmington, MA) were used to obtain subcutaneous inguinal adipose fat deposits. All rats were acclimated to the established light cycle, temperature, and feeding schedules of our animal colony for one week prior to tissue dissection. All animal care and animal dissections were in accordance with the Guide for Care and Use of Laboratory Animals (Public Health Service, 19965, NIH Publication No. 85-23).

Isolation of ASCs

The ASC isolation protocol is derived from the isolation techniques described in Yamamoto (2007) and Gronthos (2001). Briefly, excised adipose tissue was stored in a transfer medium (TM) [Dulbecco's phosphate buffered saline (DPBS, Invitrogen), 2% antibiotic/antimycotic (ABAM, Invitrogen)] and placed in an ice bath until processed. The adipose tissue was removed from the TM and rinsed in 70% EtOH and DPBS. After rinsing, the adipose tissue was finely minced using forceps and a razor blade. The minced tissue was then placed in dissociation medium (DM) [DPBS, 1% Trypsin (.25%)/EDTA (Invitrogen), and 0.1% Collagenase I (Invitrogen) filtered through a 0.22 μ m Steriflip (Millipore)] and set in a 37° shaking water bath for 20 minutes. Once dissociation was complete, the buoyant top layer, containing undissociated adipose tissue, was removed and the remnant was filtered through a 70 μ m mesh filter. The sample was then centrifuged at 500 $\times$ g for 10 min, the supernatant was aspirated, and the pellet was resuspended in growth medium (GM) [Dulbecco's modified eagle medium (DMEM, Invitrogen), 20% fetal bovine serum (FBS, Invitrogen), 1% ABAM] supplemented with 6 ng/ml FGF-2 (Peprotech). The cell suspension was preplated for 4 hours at which point the medium was changed, removing and discarding non-adherent cells. This ASC passage 0 culture was re-fed 4 days later with FGF-2 supplemented GM. The ASC culture was then fed FGF-2 supplemented GM every other day until the monolayer became >90% confluent at which point the cells were passaged. The purity of the cell population was promoted by repeated passaging and by forcefully rinsing the newly seeded ASCs within the first few hours after passaging to allow for the more adherent cells to attach as recommended (Locke, 2011). ASCs were passaged 3 times before being used in any differentiation protocol. Undifferentiated ASCs at passage 3 were fixed and assessed for the expression of cell surface markers CD90 and CD271.

Undifferentiated ASCs were continually passaged in GM supplemented with 6 ng/ml FGF-2 until they were induced into a fibroblast or nerve lineage as described below. To test the rate of proliferation when FGF-2 was supplemented in the GM, 50,000 undifferentiated ASCs were seeded in a 48 well plate and given GM with and without FGF-2. To allow the ASCs to reach their first logarithmic growth phase ASCs were fed for four days before being counted (Zhu, 2008). The doubling time (T_d) was assessed in order to determine the rate of proliferation. Doubling time was calculated using time of seeding (t_1), time of assessment (t_2), seeding cell density (q_1), and living cells at t_2 (q_2) in the following equation.

$$T_d = (t_2 - t_1) \cdot \frac{\log 2}{\log (q_2 / q_1)}.$$

Cell viability was confirmed utilizing Trypan blue stain (Gibco) during cell counting.

Fibroblast Differentiation

The cell source for fibroblast differentiation was a portion of undifferentiated ASC plates once they had been passaged 3 times. The ASCs were seeded in 60 mm tissue culture-treated plates at approximately 400,000 cells. ASCs were seeded in GM supplemented with 6 ng/ml FGF-2 and 130 μ g/ml Ascorbic Acid-2-phosphate with 50 μ g/ml proline (AA2P, Sigma Aldrich). Plates were fed supplemented GM every other day for at least 5 days until the monolayer reached >90% confluence. At this confluence level, several plates of cells were fixed in 4% paraformaldehyde (PFA) and stained for Collagen 1 to validate the induction and differentiation into the fibroblast lineage. The remaining plates were used to fabricate conduits.

The optimal concentration of FGF-2 and AA2P to induce ASCs to fibroblasts was evaluated by growing ASCs in GM with different concentrations of both growth factors. The initial concentrations of 6 ng/ml FGF-2 and 130 μ g/ml AA2P were established previously (Ma 2009). Concentrations of 6, 3, and 0 ng/ml FGF-2 were tested in combination with 130, 65, and 0 μ g/ml AA2P. Fifty thousand undifferentiated ASCs were seeded in a 48 well plate and fed GM with FGF-2 and AA2P for 3 days at which time plates were fixed with 4% PFA and stained for Col1A1. Optimal concentrations of FGF-2 and AA2P were determined by measuring the percent of Col1 positive cells produced.

Adipose-derived stem cell engineered fibroblast conduit (aEFC) fabrication

Following 5 to 7 days on GM, the fibroblasts became confluent monolayers of cells. Once the ASCs were induced to a fibroblast lineage and reached >90% confluence, the medium was switched to differentiation medium (DM) [DMEM, 7% horse serum (Invitrogen), 1% ABAM] supplemented with 6 ng/ml FGF-2, 130 μ g/ml Ascorbic Acid-2-phosphate with 50 μ g/ml Proline, and 12 ng/ml transforming growth factor TGF- β 1 (Peprotech). The supplemented DM was changed every other day for 7–10 days until the edges of the monolayer were observed to start to delaminate as a result of the passive tension of the fibroblasts. If unconstrained, the passive tension in the monolayer would eventually result in full delamination from the plate and contraction into a spherical mass of tissue. However at the onset of delamination, the fibroblast monolayer was transferred to a sylgard-coated dish (WPI) and constraint pins were placed in the dish such that the monolayer rolled into a cylindrical form which could then be used as a conduit. The monolayer was then held 16 to 24 mm apart in the dish using minuten constraint pins. The forming EFCs were fed GM every other day until the conduits were observed to become taut at which point they were frozen in Tissue Tek (Fisher) and preserved for histology.

Neurosphere induction

The neurosphere induction protocol was derived from methods used by Radtke (2009) and Bunnell (2008). ASCs were obtained from primary ASC culture at passage 3 or later. ASCs were seeded on Pyrex plates (Falcon) at 1,000 cells per ml of neuralbasal medium (NBM) supplemented with 1% N2 (Invitrogen), 1% ABAM, 1% B27 (Invitrogen), 10 ng/ml epidermal growth factor [EGF (Invitrogen)], and 10 ng/ml FGF-2. N2 and B27 are commonly used, serum-free, growth factor cocktails which are used to promote and sustain neural growth. Neurosphere cultures were observed for 3 days, replenishing EGF and FGF-2 each day. The concentrations of EGF and FGF-2 needed to induce ASCs to neurospheres were evaluated by observing the amount and size of the neurospheres produced when varying concentrations were added to the induction medium. Fifty thousand undifferentiated ASCs were seeded on sylgard coated 12 well plates in NBM supplemented with N2, ABAM, B27, and various concentrations of EGF and FGF-2. On day 3, phase contrast images were taken to assess the count and size of neurospheres. These neurospheres were then transferred to adherent tissue culture treated dishes to induce glial-like cell differentiation.

To differentiate neurospheres to glial-like cells, free-floating neurospheres were collected and centrifuged at $800 \times g$ for 10 minutes. Pelleted neurospheres were resuspended in NBM supplemented with B27. These cultures were fed B27 supplemented NBM every other day for 7–10 days either on tissue-culture treated dishes (then fixed for histology) or on top of an ASC-induced fibroblast monolayer for adipose-derived stem cell engineered neural conduit (aENC) formation.

Neurosphere differentiation into glial-like cells was accomplished using differentiation medium [(DM), NBM supplemented with 1% B27, 1% ABAM, and 1% N2]. To test the effects of serum and growth factors on neurospheres, experimental treatments were fed DM with 10 % FBS, DM with 10 ng/ml EGF and 10 ng/ml FGF-2, or serum-based growth medium (GM). The neurospheres were fed DM for 3 days at which point the neurospheres were assessed for ability to attach and extend neural processes. Successful differentiation was determined by the size and number of neurospheres produced as well as the presence of neural processes and neural marker S100.

Adipose-derived stem cell engineered neural conduit (aENC) fabrication

After ASC-induced fibroblast monolayers reached >80% confluence on GM, neurospheres were seeded on top of them. The co-culture was fed NBM supplemented with B27, so as to allow for expansion of the neural cells while simultaneously arresting the growth of the fibroblasts. After 7–10 days, a neural network was established and the cells were fed FGF-2 and AA2P supplemented GM to recover the fibroblasts. After ~3 days the medium was switched to TGF- β 1 and AA2P supplemented DM, as in the case of the aEFCs. The supplemented DM was changed every other day for 7–10 days until the edges of the monolayer were observed to start to delaminate at which point the monolayer was manually formed into a cylinder, transferred to a sylgard-coated dish, and pinned in place. Once pinned, the aENCs were fed GM until taut, at which point they were frozen in Tissue Tek and preserved for histology.

Histology

For immunohistochemical analysis, cell populations were rinsed in DPBS (3 times for 10 minutes each) then fixed with 4% paraformaldehyde for 45 minutes. Cells were permeabilized with 0.2 % Triton X-100 (Sigma) for 10 minutes, followed by a 30 minute blocking step in 5% Donkey Serum (Sigma). Cells were incubated overnight at 4°C with primary antibodies [Coll1, S100 (Santa Cruz), CD90, or CD271 (abcam)] at a dilution of

1:100. They were then incubated with AlexaFluor 488 or 555-conjugated secondary antibodies (Abcam) for 1 hour at room temperature followed by incubation with 2% DAPI for 5 minutes. Fluorescent and phase images were acquired using a Leica DMIRB inverted microscope fitted with an Olympus DP30BW high sensitivity gray scale CCD camera. Images were captured at 5×, 10×, or 40× objectives.

Statistics

Statistical comparisons were performed using values of means $\pm$ standard error (SE) to determine statistical significance. When two groups were compared the student's T-test was performed. Comparisons of 3 groups or more were performed by one-way ANOVA tests. Statistical significance was recognized at $p < 0.05$. Differences yielding a $p < 0.001$ were also noted in the figures.

Results

Isolation of ASCs

The ASCs were observed to have spindle-shaped morphology, beginning at passage 0 and through passage 12 (Figure 1). Undifferentiated ASC populations from passage 0 exhibited negative staining for adipocyte dye, Oil Red O (Sigma Aldrich). Immunohistochemical analysis revealed that undifferentiated ASC populations from passage 3 stained positive for surface markers CD90 (98%) and CD271 (96%).

Optimizing Proliferation with FGF-2

Our current protocol utilizes growth medium supplemented with FGF-2 to increase the rate of proliferation of the undifferentiated ASCs. Rate of proliferation or doubling time (T_d) was calculated for proliferation experiments in growth medium (GM) with and without FGF-2. The total cell count after 3 days *in vitro* was taken and compared to the initial seeding density utilizing the doubling time equation (Zhu, 2008). The T_d values were entered on a scatter plot to assess the changes in proliferation rates of ASC populations at passages 1, 9, and 20, both with and without the addition of 6 ng/ml FGF-2 (Figure 1B). Proliferation was slower for cells at later passages. ASCs which were given FGF-2 decreased T_d by 20% in passage 1 and 9, and by 25% in passage 20.

Fibroblast Differentiation

During the induction phase of fibroblast differentiation (between 5–7 days) and before reaching confluence, over 90% of the differentiated ASCs expressed the fibroblast marker Col1 (Figure 2A). The effects of varying concentrations of FGF-2 and AA2P with proline on fibroblast induction and differentiation was quantified by calculating the percentage of cells staining positively for Col1 (Figure 2C). Treatments with no growth factors or only FGF-2 (6 ng) resulted in a minimal percentage of Col1 positive cells [5–10% (Figure 2B)]. The addition of 6 ng of FGF-2 increased the Col1 positive cell population to 73%. The treatment using only AA2P (130 μ g) with proline (50 μ g) and no FGF-2, increased fibroblast differentiation to 50% Col1 positive cells. Thus, the optimal concentrations of growth factors for differentiation were 130 μ g of AA2P with 50 μ g proline and 6 ng FGF-2 which resulted in 90% Col1 positive cells. Once confluent and fed DM, the fibroblast monolayer was observed undergoing delamination due to the switch to low serum media (Figure 3A). The monolayer was manually formed into a cylinder and held in place by constraint pins. The conduit remodeled into a 16–24 mm long fibroblast conduit, referred to as an aEFC (Figure 3B).

Neurogenesis

Neurosphere aggregates were observed to form on non-adherent Pyrex® plates in EGF and FGF-2 supplemented serum-free NBM (Figure 4A). When transplanted to an adherent surface and fed NBM without supplemented growth factors, the neurospheres attached and formed neural processes (Figure 4B–D). These glial-like cells were shown to be distinct from the ASC-derived fibroblasts in co-culture, staining negative for Coll and positive for S100 (Figure 5B).

Neurosphere induction was tested using 9 combinations of 0, 5, and 10 ng/ml of both EGF and FGF-2. The number and cross sectional area of neurospheres per well were calculated (Figure 6). When both EGF and FGF-2 were absent from the induction medium no neurospheres were observed. It was observed that the concentration of 10 ng/ml EGF in combination with 10 ng/ml FGF-2 was optimal for neurosphere induction (Figure 6). With treatments using less than 10 ng/ml EGF and 10 ng/ml of FGF-2, fewer and smaller neurospheres were observed. Treatments with only EGF supplementation gave rise to larger neurospheres ($432 \mu\text{m}^2$) than treatments with only FGF-2 ($158 \mu\text{m}^2$). The treatments with 10 ng/ml of EGF in combination with either 10 ng/ml or 5 ng/ml of FGF-2 gave rise to the largest neurospheres ($675\text{--}750 \mu\text{m}^2$). However the treatment with 10 ng/ml of EGF and 10 ng/ml of FGF-2 produced significantly more neurospheres (1.06×10^5) than treatments of 10 ng/ml of EGF with only 5 ng/ml of FGF-2 (3.75×10^4).

The glial-like cell differentiation of neurospheres was confirmed by the presence of S100 positive cells (Figure 5B). When neurospheres were seeded in serum-based medium (GM or NBM with 20% FBS) one of two observations was made. Either the cells did not attach to the dish, or the resulting cells returned to a spindle-shaped undifferentiated morphology with no processes. Neurospheres seeded in NBM with EGF and FGF-2 resulted in similar glial-like cells as compared to the neurospheres seeded in only NBM (Figure 5).

Conduit Formation

Like the aEFC previously described, the co-culture of glial-like cells and ASC-derived fibroblasts delaminated and formed a 3-dimensional engineered neural conduit, aENC, (Figure 7A). The length of the aENCs was pre-customized between 20 and 45 mm depending on the size of the dish in which the monolayer was made (Figure 7A). The thickness of the aENCs was measured at a range of 0.3 to 1.0 mm. Histology of the aENC was performed 7 days after formation and revealed fibroblasts forming an epineurial-like sheath surrounding an inner neural network (Figure 7B). The fibroblasts of the aENC stained positive for Coll and were observed encasing the conduit as well as throughout the center. The S100 positive glial-like cells were observed within the conduit.

Discussion

The purpose of this study was to fabricate and characterize a novel scaffold-less 3-D tissue-engineered neural conduit composed of adipose-derived stem cells (ASC). This adipose-derived stem cell engineered neural conduit (aENC) consisted of an outer sheath of fibroblast cells and an inner network of glial-like neural cells. The utilization of ASC addresses and eliminates the most limiting factor in successful repair of peripheral nerve injuries, availability of autologous nerve tissue. The ASCs used in the fabrication of the aENC are abundant and biocompatible and thus eliminate the concerns of availability and immune rejection which are observed with most engineered conduits. Immunohistochemical analysis of the ASC derived aENC indicates that a 3-D nerve conduit with a fibroblast exterior and interior neural network was successfully engineered. Thus, this scaffoldless 3-D

ASC-derived nerve-fibroblast conduit may show potential for replacement of damaged nerve tissue.

While its adhesive properties facilitated the isolation of ASCs, we confirmed the expression of cell surface markers CD90 and CD271 at passage 3. We decided to utilize marker CD271, also known as p75NTR, to identify our ASC population because of its supposed potential to be a solely distinguishing marker for ASCs. The presence of the CD90 marker was used to further confirm ASC identification.

Current technologies related to neural tissue engineering focus on using nerve guidance channels for the repair of peripheral nerve injury (Ray, 2009; Deumens, 2010). These scaffolded guidance channels are often incorporated with combinations of Schwann cells, stem cells, and neurotrophic factors which direct and enhance growth of regenerating nerve (Hudson, 2000). While these engineered conduits have found success with small peripheral nerve defects, they are still faced with several drawbacks associated with the use of scaffolds, including biocompatibility, immune rejection, poor cell adhesion, and mediocre tissue repair. The need for a more biocompatible, readily available engineered conduit for repair of larger defects persists. The experiments conducted here present the technology for the development of a scaffoldless 3-D engineered neural conduit from a readily available, biocompatible source of cells, ASCs, which overcomes the drawbacks associated with current autograft and scaffold-based technologies.

Recent studies have investigated the use of ASCs as a source of support cells incorporated into nerve conduits (Locke, 2011). The use of these support cells has shown promising yet limited success in enhancing nerve regeneration during peripheral nerve recovery. Use of undifferentiated ASCs in tissue regeneration is difficult to assess due to technical issues leading to permanently inducing ASCs to the appropriate lineage *in vivo*, or apoptosis of ASCs during recovery. In 2009, Santiago et al. seeded undifferentiated ASCs in polycaprolactone synthetic conduits and utilized these conduits to repair small gaps in the sciatic nerve of adult rats. The utilization of the ASC-incorporated conduit in this repair model showed efficacy in regaining innervation to and preventing atrophy of the target muscle. However, these ASCs were incapable of differentiating solely to a neural lineage. While few of the ASCs were positive for Schwann cell markers, some cells differentiated to unwanted adipocytes, and many of them remained undifferentiated. The random fates of these ASCs *in vivo* may lead to varied results in terms of nerve recovery.

The use of ASC-induced neural cells in tissue regeneration is difficult due to issues leading to permanently inducing ASCs to the appropriate lineage *in vitro*, prevention of revision of the induced ASCs back to a mesenchymal state *in vivo*, or apoptosis of ASCs either *in vivo* or *in vitro*. In a separate study, di Summa et al. incorporated ASC-incuded neural cells in a scaffold-based system and implanted them into a peripheral nerve repair (di Summa, 2011). These conduits incorporated with ASC-induced neural cells resulted in more robust nerve regeneration and muscle recovery than conduit incorporated with either bone-marrow derived mesenchymal stem cells induced to neural cells or conduits incorporated with primary Schwann cells (di Summa, 2011). However, beta-mercaptoethanol and forskolin were used to terminally differentiate ASC to a neural lineage. The utilization of such cytotoxic compounds may not be translationally relevant. In contrast, our scaffold-less technology overcomes these limitations by permanently inducing ASCs to fibroblasts and glial-like cells by utilizing growth factors found naturally in a regenerating tissue such as FGF- 2, ascorbic acid, EGF, and TGF- β 1. Our methodology presents a more clinically relevant model for conduit technologies used in peripheral nerve repair.

In addition to the potential concerns with terminal differentiation of our ASC cell population there are issues with the morphology of terminally induced neuronal cells for use in tissue engineering. This concern arises due to the fact that mesenchymal cells induced to a neural lineage very quickly take on a more phenotypically developed morphology, extend neural processes radially from the cell, and attach to the substrate on which the cell is growing. Releasing these neural-induced cells and their neuronal processes in order to incorporate them into a conduit may damage the processes, lose the integrity of the cell, and lead to apoptosis. Thus, incorporation of neural-induced ASCs before the formation of neuronal processes and attachments was novel and essential for use as a cell source in our conduit approach.

Several laboratories have developed methodologies to induce mesenchymal stem cells to a neural lineage in glass cell culture dishes where the cells remain in suspension and aggregate into free floating neurospheres (Radtke, 2009; Bunnell, 2010). When these neurospheres are transferred onto an adherent surface in serum-free medium, they attach and extend neural processes. To date these neurospheres have only been used *in vitro* to study the proliferation of neural cells from explanted dorsal root ganglia (Radtke, 2009). We hypothesized that this neurosphere technology could be applied to our scaffold-less engineered conduit technology such that the co-culture of a fibroblast monolayer seeded with ASC-induced neurospheres would result in the successful fabrication of a functional neural conduit. In our laboratory, we successfully induced ASC to neurospheres. When these neurospheres were co-cultured with a confluent monolayer of fibroblasts, we successfully fabricated a 3-D construct, resulting in the formation of an adipose-cell derived scaffold-less engineered neural conduit, or aENC.

In conclusion, we successfully differentiated ASC to fibroblasts and glial-like cells. We were able to co-culture both of these cell types and maintain their distinct cell lineages. Finally, we fabricated scaffold-less 3-D tissue-engineered neural conduits from these co-cultures. These conduits have the potential to repair peripheral nerve traumas and represent a novel scaffold-less tissue engineering technology.

Acknowledgments

This research was supported by a NIH, NIAMS, NIBIB funded grant R01 AR054778-02 and from the Barbara and Richard Raynor Medical Foundation Award. We acknowledge Rose Lee and Mike Williams for technical assistance.

References

- Alluin O, Wittmann C, Marqueste T, Chabas JF, Garcia S, Lavaut MN, et al. Functional recovery after peripheral nerve injury and implantation of a collagen guide. *Biomaterials*. 2009; 30(3):363–373. [PubMed: 18929405]
- Baltich J, Hatch-Vallier L, Adams AM, Arruda EM, Larkin LM. Development of a scaffoldless three-dimensional engineered nerve using a nerve-fibroblast co-culture. *In Vitro Cellular & Developmental Biology Animal*. 2010; 46(5):438–444. [PubMed: 19997868]
- Bossolasco P, Cova L, Calzarossa C, Rimoldi SG, Borsotti C, Deliliers GL, et al. Neuro-glial differentiation of human bone marrow stem cells in vitro. *Experimental Neurology*. 2005; 193(2): 312–325. [PubMed: 15869934]
- Bunnell BA, Estes BT, Guilak F, Gimble JM. Differentiation of adipose stem cells. *Methods in Molecular Biology* (Clifton, NJ). 2008; 456:155–171.
- di Summa PG, et al. Long-term in vivo regeneration of peripheral nerves through bioengineered nerve grafts. *Neuroscience*. 2011; 181(5):278–291. [PubMed: 21371534]

- Deumens R, Bozkurt A, Meek MF, Marcus MA, Joosten EA, Weis J, et al. Repairing injured peripheral nerves: Bridging the gap. *Progress in Neurobiology*. 2010; 92(3):245–276. [PubMed: 20950667]
- Flores E, Orozco A, Gonzalez O, Carrasco A, Gazarian K, Cuneo S. The CD271 expression could be alone for establisher phenotypic marker in Bone Marrow derived mesenchymal stem cells. *Folia Histochem Cytobiol*. 2010; 48(4):682–6. [PubMed: 21478116]
- Griesche N, Luttmann W, Luttmann A, Stammermann T, Geiger H, Baer P. A simple modification of the separation method reduces heterogeneity of adipose-derived stem cells. *Cells Tissues Organs*. 2010; 192(2):106–15. [PubMed: 20185896]
- Gronthos S, Franklin DM, Leddy HA, Robey PG, Storms RW, Gimble JM. Surface protein characterization of human adipose tissue-derived stromal cells. *Journal of Cellular Physiology*. 2001; 189(1):54–63. [PubMed: 11573204]
- Hudson TW, Evans GR, Schmidt CE. Engineering strategies for peripheral nerve repair. *The Orthopedic Clinics of North America*. 2000; 31(3):485–498. [PubMed: 10882473]
- Kang SK, Putnam LA, Ylostalo J, Popescu IR, Dufour J, Belousov A, et al. Neurogenesis of rhesus adipose stromal cells. *Journal of Cell Science*. 2004; 117(Pt 18):4289–4299. [PubMed: 15292397]
- Locke M, Feisst V, Dunbar PR. Concise review: Human adipose-derived stem cells (ASC): Separating promise from clinical need. *Stem Cells (Dayton, Ohio)*. 2011
- Locke M, Windsor J, Dunbar PR. Human adipose-derived stem cells: Isolation, characterization and applications in surgery. *ANZ Journal of Surgery*. 2009; 79(4):235–244. [PubMed: 19432707]
- Lundborg, G. *Nerve Injury and Repair*. New York: Longman Group UK; 1988.
- Ma J, Goble K, Smietana M, Kostrominova T, Larkin L, Arruda EM. Morphological and functional characteristics of three-dimensional engineered bone-ligament-bone constructs following implantation. *Journal of Biomechanical Engineering*. 2009; 131(10):101017. [PubMed: 19831487]
- Meek MF, Coert JH. Synthetic nerve guide implants in humans: A comprehensive survey. *Neurosurgery*. 2007; 61(6):E1340. author reply E1340. [PubMed: 18162877]
- Millesi, H. Indications and techniques of nerve grafting. In: Gelvertman, RH., editor. *Operative nerve repair and reconstruction*. Philadelphia: Lippincott JB; 1991. p. 525–544.
- Mitchell JB, McIntosh K, Zvonic S, Garrett S, Floyd ZE, Kloster A, et al. Immunophenotype of human adipose-derived cells: Temporal changes in stromal-associated and stem cell-associated markers. *Stem Cells (Dayton, Ohio)*. 2006; 24(2):376–385.
- Mosna F, Sensebe L, Krampera M. Human bone marrow and adipose tissue mesenchymal stem cells: A user's guide. *Stem Cells and Development*. 2010; 19(10):1449–1470. [PubMed: 20486777]
- Puetzer JL, Petite JN, Lobo EG. Comparative review of growth factors for induction of three-dimensional in vitro chondrogenesis in human mesenchymal stem cells isolated from bone marrow and adipose tissue. *Tissue Engineering Part B, Reviews*. 2010; 16(4):435–444. [PubMed: 20196646]
- Radtke C, Schmitz B, Spies M, Kocsis JD, Vogt PM. Peripheral glial cell differentiation from neurospheres derived from adipose mesenchymal stem cells. *International Journal of Developmental Neuroscience* : The Official Journal of the International Society for Developmental Neuroscience. 2009; 27(8):817–823. [PubMed: 19699793]
- Ray WZ, Mackinnon SE. Management of nerve gaps: Autografts, allografts, nerve transfers, and end-to-side neurorrhaphy. *Experimental Neurology*. 2010; 223(1):77–85. [PubMed: 19348799]
- Rooney GE, Howard L, O'Brien T, Windebank AJ, Barry FP. Elevation of cAMP in mesenchymal stem cells transiently upregulates neural markers rather than inducing neural differentiation. *Stem Cells and Development*. 2009; 18(3):387–398. [PubMed: 18554089]
- Santiago LY, Clavijo-Alvarez J, Brayfield C, Rubin JP, Marra KG. Delivery of adipose-derived precursor cells for peripheral nerve repair. *Cell Transplantation*. 2009; 18(2):145–158. [PubMed: 19499703]
- Schmidt CE, Leach JB. Neural tissue engineering: Strategies for repair and regeneration. *Annual Review of Biomedical Engineering*. 2003; 5:293–347.
- Shokouhi G, Tubbs RS, Shoja MM, Hadidchi S, Ghorbanihaghjo A, Roshangar L, et al. Neuroprotective effects of high-dose vs low-dose melatonin after blunt sciatic nerve injury. *Child's*

- Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery. 2008; 24(1):111–117.
- Taras JS, Nanavati V, Steelman P. Nerve conduits. Journal of Hand Therapy : Official Journal of the American Society of Hand Therapists. 2005; 18(2):191–197. [PubMed: 15891977]
- Yamamoto N, Akamatsu H, Hasegawa S, Yamada T, Nakata S, Ohkuma M, et al. Isolation of multipotent stem cells from mouse adipose tissue. Journal of Dermatological Science. 2007; 48(1): 43–52. [PubMed: 17644316]
- Zhang Y, Luo H, Zhang Z, Lu Y, Huang X, Yang L, et al. A nerve graft constructed with xenogeneic acellular nerve matrix and autologous adipose-derived mesenchymal stem cells. Biomaterials. 2010; 31(20):5312–5324. [PubMed: 20381139]
- Zhu Y, Liu T, Song K, Fan X, Ma X, Cui Z. Adipose-derived stem cell: A better stem cell than BMSC. Cell Biochemistry and Function. 2008; 26(6):664–675. [PubMed: 18636461]

Highlights

- Adipose-derived stem cells were differentiated to a fibroblast or neural lineage.
- ASC differentiated to neurospheres and co-cultured into 3-D tissue engineered neural conduits.
- ASC neural conduit could be efficacious for repairing critical gaps in peripheral nerve injury.

Figure 1. Spindle shaped morphology of undifferentiated ASCs at passage 3. Phase contrast at 40 $\times$ magnification (A). Doubling time (T_d) of ASCs at different passage number and with or without the addition of FGF-2 added to the growth medium (B). The addition of FGF-2 to undifferentiated ASCs significantly decreased their T_d . The statistical significance of the addition of FGF-2 to undifferentiated ASCs increased in later passages as compared to earlier passages. * $p < 0.05$, compared to treatments with 6 ng/ml FGF-2.

Figure 2.

Percentage of ASCs differentiated to fibroblasts. Differentiation of ASCs to fibroblasts was observed by the presence of Collagen-1. Col1 (red) DAPI (blue) at 40× magnification in control treatments, given no FGF-2 or ascorbic acid 2-phosphate (A) and in the optimal treatment, given 130 µg AA2P and 6 ng FGF-2 (B). Col1 positive cells were counted and compared to the total number of cells using DAPI to determine the percent differentiated (C). Differentiation medium with no FGF-2 and AA2P was used as a negative control, 4%. The addition of just FGF-2 increased the fibroblast differentiation of ASCs to 9%. The addition of any amount of AA2P with or without FGF-2 resulted in 50–60% Col1 positive ASC-induced fibroblasts. Differentiation medium which included both FGF-2 and AA2P (51–90%) gave rise to significantly more fibroblasts than media with only FGF-2 (9%). * $p < 0.05$, compared to negative control; † $p < 0.05$, compared to treatment with no AA2P and 6 ng/ml FGF-2.

Figure 3. Delamination (marked by arrows) of the ASC-derived fibroblast monolayer from the edges of the tissue culture plate (A). Three-dimensional formation of aEFC (engineered fibroblast conduit fabricated only from ASC-derived fibroblasts) at 16 mm length *in vitro* held in place by constraint pins (B).

Figure 4. Neurospheres were observed as free-floating aggregates of cells (A) which began to attach 1 day after being transferred to an adherent surface (B). On day 3 more cells were observed attaching to the plate (C) By day 7, nearly all cells from the neurosphere attached to the plate and extended neural processes (D). Phase contrast at 40× magnification.

Figure 5.

In co-culture with ASC-derived fibroblasts monolayer (black arrow), neurospheres (white arrow) were observed attaching and expanding on the fibroblast monolayer (A). Phase contrast at 40× magnification. The glial-like cells (small arrows) coming from the neurosphere (large arrow) migrated onto the fibroblast monolayer as indicated by positive staining for Schwann cell marker S100 (A). S100 (green) DAPI (blue) at 40× magnification.

Figure 6. Neurosphere induction at different concentrations of EGF and FGF-2. Between 30 and 80 neurospheres were measured from each treatment to find the average cross sectional area, CSA (A). Without EGF or FGF-2 no neurospheres accumulated. Treatments with 5 ng of EGF produced neurospheres of a statistically similar CSA with or without the addition of FGF-2. Additionally neurospheres from treatments with 10 ng of EGF had similar CSA whether or not FGF-2 was added. The total number of neurospheres in each well for each treatment was also counted (B). The treatment with 10 ng of both EGF and FGF-2 resulted in significantly more neurospheres per well than any other treatment. All other treatments yielded no significant difference from each other. * $p < 0.05$, compared to negative control; † $p < 0.05$, compared to treatment with 0 ng/ml EGF and 5 ng/ml FGF-2; ‡ $p < 0.05$, compared to treatment with 5 ng/ml EGF and 0 ng/ml FGF-2.

Figure 7.

The three-dimensional formation of engineered neural conduit fabricated from ASC-induced fibroblasts and ASC-induced glial-like cells (aENC) at 20 mm length *in vitro* (A). Ruler is in mm. The presence of both fibroblast and glial-like cell types in the aENC cross section were confirmed using collagen marker Coll1 (green) and S100 (red) (B). Fibroblasts were observed surrounding an inner neural network.